This R50 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports Dr. Parikh's clinical research efforts at Mayo Clinic to improve chronic lymphocytic leukemia (CLL) patient care through novel NCI-sponsored clinical trials.
The $124,230 award (with an end date of July 31, 2029) will enable Dr. Parikh to: 1) complete two ongoing NCI clinical trials evaluating combination therapies for untreated CLL patients, and participate in the data analysis and publication of results; and 2) develop the protocol and serve as national principal investigator for a new ECOG-ACRIN-led frontline CLL clinical trial. Through this work, Dr. Parikh aims to advance the understanding and treatment of CLL, a common form of adult leukemia, in collaboration with the National Clinical Trials Network.
Generated 1/28/25, 10:46 AM